ASX - By Stock
|
ATH |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
shlok
|
16 |
3.4K |
5 |
30/04/24 |
30/04/24 |
ASX - By Stock
|
16
|
3.4K
|
5
|
|
ASX - By Stock
|
ATH Biotech |
Re:
Orphan drug week - 22nd to 26th April
|
|
shlok
|
24 |
6.4K |
2 |
27/04/24 |
27/04/24 |
ASX - By Stock
|
24
|
6.4K
|
2
|
|
ASX - By Stock
|
ATH Biotech |
Re:
Orphan drug week - 22nd to 26th April
|
|
shlok
|
24 |
6.4K |
2 |
27/04/24 |
27/04/24 |
ASX - By Stock
|
24
|
6.4K
|
2
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Quarterly Appendix 4C and Activities Report
|
|
shlok
|
48 |
14K |
1 |
24/04/24 |
24/04/24 |
ASX - By Stock
|
48
|
14K
|
1
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Quarterly Appendix 4C and Activities Report
|
|
shlok
|
48 |
14K |
1 |
24/04/24 |
24/04/24 |
ASX - By Stock
|
48
|
14K
|
1
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Quarterly Appendix 4C and Activities Report
|
|
shlok
|
48 |
14K |
2 |
24/04/24 |
24/04/24 |
ASX - By Stock
|
48
|
14K
|
2
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Quarterly Appendix 4C and Activities Report
|
|
shlok
|
48 |
14K |
1 |
24/04/24 |
24/04/24 |
ASX - By Stock
|
48
|
14K
|
1
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Quarterly Appendix 4C and Activities Report
|
|
shlok
|
48 |
14K |
0 |
24/04/24 |
24/04/24 |
ASX - By Stock
|
48
|
14K
|
0
|
|
ASX - By Stock
|
DRO |
Re:
Ann: NATO Framework Agreement Signed
|
|
shlok
|
177 |
55K |
0 |
20/04/24 |
20/04/24 |
ASX - By Stock
|
177
|
55K
|
0
|
|
ASX - By Stock
|
ATH |
Alpha-synuclein induced synucleinopathies and NBIA's
|
|
shlok
|
10 |
3.1K |
13 |
19/04/24 |
19/04/24 |
ASX - By Stock
|
10
|
3.1K
|
13
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Alterity Parkinson's and MSA Data Featured at AAN Meeting
|
|
shlok
|
22 |
5.8K |
5 |
19/04/24 |
19/04/24 |
ASX - By Stock
|
22
|
5.8K
|
5
|
|
ASX - By Stock
|
EYE |
Re:
Nova Eye Medical (EYE) Discussion
|
|
shlok
|
2.8K |
683K |
4 |
19/04/24 |
19/04/24 |
ASX - By Stock
|
2.8K
|
683K
|
4
|
|
ASX - By Stock
|
ATH Biotech |
Re:
Week ahead - 15th April - 19th April
|
|
shlok
|
31 |
9.6K |
3 |
18/04/24 |
18/04/24 |
ASX - By Stock
|
31
|
9.6K
|
3
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Alterity Parkinson's and MSA Data Featured at AAN Meeting
|
|
shlok
|
22 |
5.8K |
2 |
18/04/24 |
18/04/24 |
ASX - By Stock
|
22
|
5.8K
|
2
|
|
ASX - By Stock
|
ATH Biotech |
Re:
Week ahead - 15th April - 19th April
|
|
shlok
|
31 |
9.6K |
1 |
16/04/24 |
16/04/24 |
ASX - By Stock
|
31
|
9.6K
|
1
|
|
ASX - By Stock
|
ATH Biotech |
Re:
Week ahead - 15th April - 19th April
|
|
shlok
|
31 |
9.6K |
3 |
15/04/24 |
15/04/24 |
ASX - By Stock
|
31
|
9.6K
|
3
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Alterity to Present New ATH434 Data at Orphan Drug Congress
|
|
shlok
|
29 |
8.1K |
2 |
12/04/24 |
12/04/24 |
ASX - By Stock
|
29
|
8.1K
|
2
|
|
ASX - By Stock
|
ATH |
Re:
another good day in New York
|
|
shlok
|
24 |
6.5K |
2 |
12/04/24 |
12/04/24 |
ASX - By Stock
|
24
|
6.5K
|
2
|
|
ASX - By Stock
|
EYE |
Re:
Nova Eye Medical (EYE) Discussion
|
|
shlok
|
2.8K |
683K |
2 |
12/04/24 |
12/04/24 |
ASX - By Stock
|
2.8K
|
683K
|
2
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Alterity to Present New ATH434 Data at Orphan Drug Congress
|
|
shlok
|
29 |
8.1K |
3 |
12/04/24 |
12/04/24 |
ASX - By Stock
|
29
|
8.1K
|
3
|
|
ASX - By Stock
|
DXB |
Re:
Dimerix (ASX: DXB) Discussion Thread
|
|
shlok
|
640 |
209K |
2 |
12/04/24 |
12/04/24 |
ASX - By Stock
|
640
|
209K
|
2
|
|
ASX - By Stock
|
ATH |
Re:
Upcoming presentation dates and time at AAN, with preliminary phase 2 timeline
|
|
shlok
|
113 |
26K |
2 |
09/04/24 |
09/04/24 |
ASX - By Stock
|
113
|
26K
|
2
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Investor Presentation
|
|
shlok
|
176 |
51K |
4 |
07/04/24 |
07/04/24 |
ASX - By Stock
|
176
|
51K
|
4
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Investor Presentation
|
|
shlok
|
176 |
51K |
7 |
04/04/24 |
04/04/24 |
ASX - By Stock
|
176
|
51K
|
7
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Investor Presentation
|
|
shlok
|
176 |
51K |
2 |
03/04/24 |
03/04/24 |
ASX - By Stock
|
176
|
51K
|
2
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Investor Presentation
|
|
shlok
|
176 |
51K |
2 |
03/04/24 |
03/04/24 |
ASX - By Stock
|
176
|
51K
|
2
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Investor Presentation
|
|
shlok
|
176 |
51K |
7 |
03/04/24 |
03/04/24 |
ASX - By Stock
|
176
|
51K
|
7
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Investor Presentation
|
|
shlok
|
176 |
51K |
16 |
03/04/24 |
03/04/24 |
ASX - By Stock
|
176
|
51K
|
16
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Investor Presentation
|
|
shlok
|
176 |
51K |
2 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
176
|
51K
|
2
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Investor Presentation
|
|
shlok
|
176 |
51K |
4 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
176
|
51K
|
4
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Investor Presentation
|
|
shlok
|
176 |
51K |
7 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
176
|
51K
|
7
|
|
ASX - By Stock
|
EYE |
Re:
Nova Eye Medical (EYE) Discussion
|
|
shlok
|
2.8K |
683K |
10 |
31/03/24 |
31/03/24 |
ASX - By Stock
|
2.8K
|
683K
|
10
|
|
ASX - By Stock
|
ATH |
Re:
Upcoming presentation dates and time at AAN, with preliminary phase 2 timeline
|
|
shlok
|
113 |
26K |
2 |
27/03/24 |
27/03/24 |
ASX - By Stock
|
113
|
26K
|
2
|
|
ASX - By Stock
|
ATH |
Re:
Upcoming presentation dates and time at AAN, with preliminary phase 2 timeline
|
|
shlok
|
113 |
26K |
3 |
27/03/24 |
27/03/24 |
ASX - By Stock
|
113
|
26K
|
3
|
|
ASX - By Stock
|
ATH |
Re:
Upcoming presentation dates and time at AAN, with preliminary phase 2 timeline
|
|
shlok
|
113 |
26K |
2 |
23/03/24 |
23/03/24 |
ASX - By Stock
|
113
|
26K
|
2
|
|
ASX - By Stock
|
ATH |
Re:
Upcoming presentation dates and time at AAN, with preliminary phase 2 timeline
|
|
shlok
|
113 |
26K |
2 |
23/03/24 |
23/03/24 |
ASX - By Stock
|
113
|
26K
|
2
|
|
ASX - By Stock
|
ATH |
Re:
Upcoming presentation dates and time at AAN, with preliminary phase 2 timeline
|
|
shlok
|
113 |
26K |
2 |
23/03/24 |
23/03/24 |
ASX - By Stock
|
113
|
26K
|
2
|
|
ASX - By Stock
|
ATH |
Re:
Upcoming presentation dates and time at AAN, with preliminary phase 2 timeline
|
|
shlok
|
113 |
26K |
2 |
22/03/24 |
22/03/24 |
ASX - By Stock
|
113
|
26K
|
2
|
|
ASX - By Stock
|
ATH |
Re:
Upcoming presentation dates and time at AAN, with preliminary phase 2 timeline
|
|
shlok
|
113 |
26K |
2 |
22/03/24 |
22/03/24 |
ASX - By Stock
|
113
|
26K
|
2
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Notification of upcoming expiry of Unlisted Options
|
|
shlok
|
93 |
23K |
4 |
22/03/24 |
22/03/24 |
ASX - By Stock
|
93
|
23K
|
4
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Notification of upcoming expiry of Unlisted Options
|
|
shlok
|
93 |
23K |
9 |
22/03/24 |
22/03/24 |
ASX - By Stock
|
93
|
23K
|
9
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Notification of upcoming expiry of Unlisted Options
|
|
shlok
|
93 |
23K |
0 |
22/03/24 |
22/03/24 |
ASX - By Stock
|
93
|
23K
|
0
|
|
ASX - By Stock
|
ATH |
Re:
Upcoming presentation dates and time at AAN, with preliminary phase 2 timeline
|
|
shlok
|
113 |
26K |
1 |
22/03/24 |
22/03/24 |
ASX - By Stock
|
113
|
26K
|
1
|
|
ASX - By Stock
|
ATH |
Re:
Upcoming presentation dates and time at AAN, with preliminary phase 2 timeline
|
|
shlok
|
113 |
26K |
2 |
21/03/24 |
21/03/24 |
ASX - By Stock
|
113
|
26K
|
2
|
|
ASX - By Stock
|
PER |
Re:
per-chart
|
|
shlok
|
657 |
158K |
2 |
20/03/24 |
20/03/24 |
ASX - By Stock
|
657
|
158K
|
2
|
|
ASX - By Stock
|
ATH |
Re:
Upcoming presentation dates and time at AAN, with preliminary phase 2 timeline
|
|
shlok
|
113 |
26K |
1 |
19/03/24 |
19/03/24 |
ASX - By Stock
|
113
|
26K
|
1
|
|
ASX - By Stock
|
ATH |
Re:
Upcoming presentation dates and time at AAN, with preliminary phase 2 timeline
|
|
shlok
|
113 |
26K |
1 |
19/03/24 |
19/03/24 |
ASX - By Stock
|
113
|
26K
|
1
|
|
ASX - By Stock
|
ATH |
Re:
Upcoming presentation dates and time at AAN, with preliminary phase 2 timeline
|
|
shlok
|
113 |
26K |
2 |
18/03/24 |
18/03/24 |
ASX - By Stock
|
113
|
26K
|
2
|
|
ASX - By Stock
|
ATH |
Re:
Upcoming presentation dates and time at AAN, with preliminary phase 2 timeline
|
|
shlok
|
113 |
26K |
2 |
18/03/24 |
18/03/24 |
ASX - By Stock
|
113
|
26K
|
2
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Dimerix Successfully Passes Efficacy Interim Analysis
|
|
shlok
|
279 |
86K |
5 |
17/03/24 |
17/03/24 |
ASX - By Stock
|
279
|
86K
|
5
|
|